Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies designed to guide the immune system and help patients gain control over disease. Its focus includes immunology and inflammatory conditions, with antigen-specific approaches intended to influence T-cell responses. The company’s broader work targets chronic viral infections, autoimmune diseases, and cancer, aiming to advance treatments that improve patients’ lives.

Barinthus develops investigational therapies through a clinical pipeline and evaluates them in clinical studies. Its programs include VTP-200, studied in women with low-grade human papillomavirus-related cervical lesions, and VTP-300, investigated for chronic hepatitis B. The company has reported interim findings for VTP-200 and positive topline final results from its HBV002 study of VTP-300, including sustained reductions in hepatitis B surface antigen. These are investigational programs, and the information provided does not indicate that the therapies are approved for general use.

The company also shares pipeline updates, clinical news, financial reports, and investor information. Barinthus emphasizes patients and their families as central to its mission, values, and organizational culture.